Ovarian cancer screening using serum CA125 and transvaginal ultrasound: A systematic review and meta-analysis

Background: The clinical utility of ovarian cancer screening remains unclear. This study aims to evaluate the effectiveness of serum cancer antigen 125 combined with transvaginal ultrasound in the early detection of ovarian cancer and the improvement of prognosis. Methods: Systematically searched five electronic databases to identify eligible randomised controlled trials. The primary outcomes were ovarian cancer incidence and ovarian cancer-specific mortality. Results were evaluated using relative risks and 95% confidence intervals. Results: Four randomised controlled trials were included in this meta-analysis, comprising 188147 participants in the screening group and 187394 in the control group. Pooled results showed no statistically significant difference in overall ovarian cancer incidence and ovarian cancer-specific mortality between the two groups (all p>0.05). Subgroup analysis further showed that the screening group had a significantly higher detection rate of Stage I ovarian cancer than the control group (relative risks=1.35, 95% confidence interval:1.14–1.60; p<0.001). For histological subtypes, the screening group had a significantly higher detection rate of serous carcinoma (relative risk=1.09, 95% confidence interval:1.01-1.19; p=0.030), but a significantly lower detection rate of mucinous carcinoma (relative risk=0.69, 95% confidence interval:0.51–0.94; p=0.020). No statistically significant difference was observed between the two groups in other subgroups (all p>0.05). Conclusion: For asymptomatic women in the general population, combined serum cancer antigen 125 and transvaginal ultrasound screening should be approached with caution. Current evidence indicates that this screening strategy neither reduced​ the overall incidence of ovarian cancer nor improved​ overall survival, despite potentially increasing the detection rate of Stage I and early-stage serous carcinoma.

Authors

Publication Details

Journal
Gynecologic and Obstetric Investigation
Published
2026-11-19
DOI
https://doi.org/10.1159/goi/aczag027
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ovarian cancer screening using serum CA125 and transvaginal ultrasound: A systematic review and meta-analysis

郑奇, Qianyu Dai, Yixuan Wu, Lihu Gu et al.
Gynecologic and Obstetric Investigation
Ovarian cancer diagnosis and treatment
article

Ovarian cancer screening using serum CA125 and transvaginal ultrasound: A systematic review and meta-analysis

郑奇, Qianyu Dai, Yixuan Wu, Lihu Gu, Xiaoming Zhang, Xintong Shi, yu Chen
article en

Abstract

Background: The clinical utility of ovarian cancer screening remains unclear. This study aims to evaluate the effectiveness of serum cancer antigen 125 combined with transvaginal ultrasound in the early detection of ovarian cancer and the improvement of prognosis. Methods: Systematically searched five electronic databases to identify eligible randomised controlled trials. The primary outcomes were ovarian cancer incidence and ovarian cancer-specific mortality. Results were evaluated using relative risks and 95% confidence intervals. Results: Four randomised controlled trials were included in this meta-analysis, comprising 188147 participants in the screening group and 187394 in the control group. Pooled results showed no statistically significant difference in overall ovarian cancer incidence and ovarian cancer-specific mortality between the two groups (all p>0.05). Subgroup analysis further showed that the screening group had a significantly higher detection rate of Stage I ovarian cancer than the control group (relative risks=1.35, 95% confidence interval:1.14–1.60; p<0.001). For histological subtypes, the screening group had a significantly higher detection rate of serous carcinoma (relative risk=1.09, 95% confidence interval:1.01-1.19; p=0.030), but a significantly lower detection rate of mucinous carcinoma (relative risk=0.69, 95% confidence interval:0.51–0.94; p=0.020). No statistically significant difference was observed between the two groups in other subgroups (all p>0.05). Conclusion: For asymptomatic women in the general population, combined serum cancer antigen 125 and transvaginal ultrasound screening should be approached with caution. Current evidence indicates that this screening strategy neither reduced​ the overall incidence of ovarian cancer nor improved​ overall survival, despite potentially increasing the detection rate of Stage I and early-stage serous carcinoma.

Gynecologic and Obstetric Investigation
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon